Purpose: To assess sensibility and specificity, positive and negative predictive values and probability of false-positive and false-negative of the water-drinking test, ibopamine test, frequency doubling perimetry, short-wave automated perimetry and daily curve of intraocular pressure in glaucoma suspects. Design: Cross-sectional study Methods: Glaucoma suspect eyes and normal control eyes from age-matched individuals, both with normal standard achromatic perimetry, were submitted to water-drinking test, ibopamine test, frequency doubling perimetry, short-wave automated perimetry and daily curve of intraocular pressure. Results: We included 45 Glaucoma suspect and 30 normal control eyes. Sensibility and specificity were respectively 75.6% and 100% for daily curve of intraocular pressure; 35.6% and 80% for ibopamine test; 22.2% and 96.7% for short-wave automated peri-metry; 15.6% and 96.7% for water-drinking test; 8.9% and 100% for frequency doubling perimetry. Positive and negative predictive values of the same workups were: 100% and 99.5%; 3.5% and 98.4%; 12% and 98.4%; 8.7% and 98.2%; 100% and 98.2%. False-positive and false-negative probabilities were: 0% and 0.5%; 96.5% and 1.6%; 91.3% and 0%; 88.0% and 1.6%; 0% and 1.9%. Conclusions: The daily curve of intraocular pressure presented the highest sensibility with the highest positive predictive value. Frequency doubling perime-try presented a very low probability of false-negative. Ibopamine test, water-drinking test and short-wave automated perimetry presented a very high probability of false-positive.

Vascular endothelial growth factor (VEGF) plays a major role in the patho-genesis of diabetic retinopathy. Its inhibition by bevacizumab, a monoclonal antibody against all VEGF isoforms, has been shown to be beneficial in the management of both diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Our group has previously demonstrated that multiple intra-vitreal injections of bevacizumab of either 1.25 or 2.5 mg in eyes with DME result in a reduction of macular edema and an improvement in visual acuity. We did not observe any differences in the outcomes between eyes treated with the lower and higher doses of bevacizumab. We also studied the effect of intravitreal bevacizumab in eyes with PDR. Intravitreal bevacizumab is capable of inducing regression of retinal and optic disc neovascularization. However this regression is not permanent and panretinal photocoagulation is needed to consolidate treatment. Caution should be exercised in eyes with advanced PDR since a rapid involution of the fibrovascular proliferation may lead to the development or the progression of a tractional retinal detachment. Thus when using intravitreal be-vacizumab as an adjuvant in diabetic vitrectomies, surgery should be scheduled no more than 4 days after injection. Resumen El factor de crecimiento vascular endotelial (VEGF) juega un rol protagónico en la patogénesis de la retino-patía diabética. Su inhibición por el Bevacizumab, un anticuerpo monoclonal contra todas las isoformas del VEGF, ha demostrado ser benéfica en el manejo tanto del edema macular diabético (EMD) como de la retinopatía diabética proliferativa (RDP). Nuestro grupo ha previamente demostrado que múltiples inyecciones intravítreas tanto de 1,25 o 2,5 mg de bevacizumab en ojos con EMD resultan en la reducción del edema macular y mejoría en la agudeza visual. No se observó diferencia alguna entre los resultados de los ojos tratados con dosis más bajas o altas del bevacizumab. Se estudió también el efecto del bevacizumab intravítreos en ojos con RDP. El bevacizumab intravítreo es capaz de inducir regresión de la neovascularización de la retina y disco óptico. Sin embargo, esta regresión no es permanente y la fotocoagulación panretiniana o vitrectomía son ne-cesarías para consolidar el tratamiento. Se debe tener cautela en ojos con RDP avanzada debido a que la rápida involución de las proliferaciones fibrovasculares pueden conllevar al desarrollo o progresión de un desprendimiento de retina traccional. Por lo tanto al utilizar el bevacizumab intravítreo como adyuvante en la vitrectomía de pacientes diabéticos, la cirugía no debe ser programada más de 4 días después de dicha inyección.